Single-center, randomized, double blind, placebo-controlled dose-escalation phase 1 study of universal influenza vaccine
Latest Information Update: 22 Dec 2021
At a glance
- Drugs Universal influenza vaccine Emergent Biosolutions (Primary)
- Indications Influenza virus infections
- Focus Adverse reactions; Pharmacodynamics
- 22 Dec 2021 New trial record
- 16 Dec 2021 According to an Emergent BioSolutions media release, first participant has been dosed in this trial and the study is fully funded by Emergent.